Evaluation of in Vivo Neuroinflammation in Parkinson's Disease Using 18F-NOS Positron Emission Tomography (PET/CT)

Who is this study for? Adult patients with Parkinson's Disease
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Early Phase 1
SUMMARY

The research study is being conducted to test how a specialized type of Positron Emission Tomography (PET/CT) scan could potentially be useful in diagnosing or monitoring treatment in people with Parkinson's disease. If the subject decide to be in this study he/she will have a PET/CT scans using an imaging drug called 18F-NOS which will be used to measure inflammation in the brain.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 75
Healthy Volunteers: Accepts Healthy Volunteers
View:

• Participants will be 18-75 years of age.

• Participants must be informed of the investigational nature of this study and be willing to provide written informed consent and participate in this study in accordance with institutional and federal guidelines prior to study-specific procedures.

• Subjects with known neuropsychiatric disorder may be eligible if, in the opinion of an investigator, the psychiatric condition would not compromise subject safety or successful participation in the study.

• History of diagnosis of probable idiopathic PD derived from UK Brain Bank Diagnostic criteria(1) per neurologist review.

• Diagnosed with Parkinson's Disease at least 3 year prior to enrollment.

• Subjects will be selected who have the capacity to give their own informed consent, in the opinion of a neurology investigator.

Locations
United States
Pennsylvania
University of Pennsylvania
Recruiting
Philadelphia
Contact Information
Primary
Erin Schubert
erinschu@pennmedicine.upenn.edu
215-573-6569
Time Frame
Start Date: August 14, 2019
Estimated Completion Date: August 2023
Participants
Target number of participants: 30
Treatments
Experimental: Patient with Parkinson Disease
Subject should have a history of diagnosis of probable idiopathic PD derived from UK Brain Bank Diagnostic criteria per neurologist review.~Subject must have been diagnosed with Parkinson's Disease at least 3 year prior to enrollment.
Experimental: Healthy Control
Subject must be a Healthy.
Sponsors
Leads: University of Pennsylvania

This content was sourced from clinicaltrials.gov

Similar Clinical Trials